<SEC-DOCUMENT>0001171843-25-000505.txt : 20250129
<SEC-HEADER>0001171843-25-000505.hdr.sgml : 20250129
<ACCEPTANCE-DATETIME>20250129161035
ACCESSION NUMBER:		0001171843-25-000505
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20250129
FILED AS OF DATE:		20250129
DATE AS OF CHANGE:		20250129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		25569438

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_012925.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date of report:
29/01/2025 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Commission
File Number: 001-38844</B></FONT><B> </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>GENFIT S.A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Translation of registrant&#8217;s
name into English) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Parc Eurasant&eacute;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>885, avenue Eug&egrave;ne
Avin&eacute;e</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>59120 Loos, France</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal
executive office) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt">Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 20-F &#9;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 40-F</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT LIST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; width: 6%"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></P></TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; width: 90%"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></P></TD></TR>
  <TR>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="exh_991.htm">99.1</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="exh_991.htm">Press Release dated 29/01/2025.</A></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: 29/01/2025</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 0pt; padding-left: 0pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; border-bottom: black 1pt solid; padding-right: 0pt; padding-left: 0pt; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="text-align: right; font: 14pt Times New Roman, Times, Serif; margin: 2.9pt 0 0"><FONT STYLE="font-size: 10pt; color: Black"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="text-align: center; font: 14pt Times New Roman, Times, Serif; margin-top: 2.9pt; margin-bottom: 0"><IMG SRC="hdr.jpg" ALT=""></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 2.9pt 0 0">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #005478"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GENFIT
Announces 2025 Financial <FONT STYLE="letter-spacing: -0.1pt">Calendar</FONT></B></FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 10.55pt 0 0"></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 10.55pt 0 0"></P>

<P STYLE="font: 10pt/115% Lucida Sans; margin: 0 5.55pt 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #005278"><B>Lille
(France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
GENFIT (Nasdaq and Euronext: GNFT)</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, a late-stage
biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening
liver diseases, today announced its provisional financial calendar for 2025.</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2025
Financial <FONT STYLE="letter-spacing: -0.1pt">Calendar</FONT></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 13.4pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; width: 50%; border: black 1pt solid; font: 11pt Lucida Sans; padding-top: 1pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.3pt">February
    27, 2025</FONT></TD>
    <TD STYLE="padding: 0pt; width: 50%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><P STYLE="font: 10pt Lucida Sans; margin: 1pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Publication of
    revenue and cash position <FONT STYLE="letter-spacing: -0.25pt">at</FONT></FONT></P>
    <P STYLE="font: 10pt/11.65pt Lucida Sans; margin: 1.75pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.4pt">December
    31, 2024</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 11pt Lucida Sans; padding-top: 1pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    24, <FONT STYLE="letter-spacing: -0.2pt">2025</FONT></FONT></TD>
    <TD STYLE="padding: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><P STYLE="font: 10pt/115% Lucida Sans; margin: 1pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt">Publication
    of Full Year 2024 financial </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.1pt">statements</FONT></P>
    <P STYLE="font: 10pt/110% Calibri, Helvetica, Sans-Serif; margin: 13.75pt 10.7pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The
    2024 Universal Registration Document and Annual Financial Report (included in the Universal Registration Document), as well as the
    Annual Report on Form 20-F will be made <FONT STYLE="letter-spacing: -0.1pt">public </FONT>by the end of April <FONT STYLE="letter-spacing: -0.2pt">2025.</FONT></I></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 11pt Lucida Sans; padding-top: 1pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.4pt">May
    22, 2025</FONT></TD>
    <TD STYLE="padding: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><P STYLE="font: 10pt Lucida Sans; margin: 1pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Publication of
    revenue and cash position <FONT STYLE="letter-spacing: -0.25pt">at</FONT></FONT></P>
    <P STYLE="font: 10pt/11.55pt Lucida Sans; margin: 1.9pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.4pt">March
    31, 2025</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 11pt/11.65pt Lucida Sans; padding-top: 1pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    17, <FONT STYLE="letter-spacing: -0.2pt">2025</FONT></FONT></TD>
    <TD STYLE="padding: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 11pt/11.65pt Lucida Sans; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.2pt">Annual
    Shareholders Meeting</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 11pt Lucida Sans; padding-top: 1pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.3pt">September
    22, 2025</FONT></TD>
    <TD STYLE="padding: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><P STYLE="font: 10pt Lucida Sans; margin: 1pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Publication of
    the half-year 2025 <FONT STYLE="letter-spacing: -0.1pt">financial</FONT></FONT></P>
    <P STYLE="font: 10pt/11.65pt Lucida Sans; margin: 1.8pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.1pt">statements</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 11pt Lucida Sans; padding-top: 1pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.3pt">November
    20, 2025</FONT></TD>
    <TD STYLE="padding: 0pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: 0pt"><P STYLE="font: 10pt Lucida Sans; margin: 1pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Publication of
    revenue and cash position <FONT STYLE="letter-spacing: -0.25pt">at</FONT></FONT></P>
    <P STYLE="font: 10pt/11.55pt Lucida Sans; margin: 1.9pt 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt">September
    30, 2025</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 2.8pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt">This
calendar is subject to change.</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 2.8pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify; color: #005478"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ABOUT
<FONT STYLE="letter-spacing: -0.1pt">GENFIT</FONT></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 4.45pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/132% Lucida Sans; margin: 0 5.6pt 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #090909; letter-spacing: -0.1pt">GENFIT
is a late-stage biopharmaceutical company committed to improving the lives of patients with</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.1pt">rare,
life-threatening liver diseases <FONT STYLE="color: #090909">whose medical needs remain largely unmet. GENFIT is a </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #090909; letter-spacing: -0.3pt">pioneer
in liver disease research and development with a rich history and a solid scientific heritage </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #090909; letter-spacing: -0.2pt">spanning
more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&amp;D portfolio of programs at various stages
of development. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt">The Company focuses on Acute-on-
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt">Chronic Liver Failure (ACLF). Its ACLF franchise
includes five assets under development: VS-01, NTZ,</FONT></P>

<P STYLE="font: 10pt/132% Lucida Sans; margin: 0 5.6pt 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/132% Lucida Sans; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt"><IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Lucida Sans; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="hdr.jpg" ALT=""></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/132% Lucida Sans; margin: 0 5.65pt 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt">SRT-015,
CLM-022 and VS-02-HE, <FONT STYLE="color: #090909">based on complementary mechanisms of action using different routes of administration.
Other assets target other serious diseases, such as cholangiocarcinoma </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #090909; letter-spacing: -0.3pt">(CCA),
urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #090909">of
high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of
Iqirvo&reg; (elafibranor<SUP>1</SUP>) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare
Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">GENFIT
also has a <FONT STYLE="letter-spacing: -0.2pt">diagnostic franchise including NIS2+&reg; in Metabolic dysfunction-associated steatohepatitis
(MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia </FONT>levels<FONT STYLE="color: #090909">.
GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich <FONT STYLE="letter-spacing: -0.3pt">(Switzerland)
and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market </FONT><FONT STYLE="letter-spacing: -0.1pt">and on
the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In </FONT><FONT STYLE="letter-spacing: -0.3pt">2021,
Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's </FONT>capital. </FONT><FONT STYLE="color: Black">www.genfit.com</FONT></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 9.8pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify; color: #005478"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FORWARD
LOOKING <FONT STYLE="letter-spacing: -0.1pt">STATEMENTS</FONT></B></FONT></P>

<P STYLE="font: 10pt/132% Lucida Sans; margin: 2.95pt 5.7pt 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt">This
press release contains certain forward-looking statements, including those within the meaning </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.1pt">of
the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, <FONT STYLE="color: #090909">including, but not limited
to statements about</FONT> GENFIT&#8217;s research and development programs and planned release </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt">of
financial information. The use of certain words, such as &quot;believe&quot;, &quot;potential&quot;, &quot;expect&quot;, &#8220;target&#8221;,
&#8220;may&#8221;, &#8220;will&#8221;, &quot;should&quot;, &quot;could&quot;, &quot;if&quot; and similar expressions, is intended to
identify forward-looking </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.3pt">statements. Although
the Company believes its expectations are based on the current expectations </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.1pt">and
reasonable assumptions of the Company&#8217;s management, these forward-looking statements </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">are
subject to numerous known and unknown risks and uncertainties, which could cause actual <FONT STYLE="letter-spacing: -0.3pt">results
to differ materially from those expressed in, or implied or projected by, the forward-looking </FONT>statements. These risks and uncertainties
include, among others, the uncertainties inherent in <FONT STYLE="letter-spacing: -0.2pt">research and development, including in relation
to safety of drug candidates, cost of, progression </FONT><FONT STYLE="letter-spacing: -0.1pt">of, and results from, our ongoing and
planned clinical trials, review and approvals by regulatory </FONT>authorities in the United States, Europe and worldwide, of our drug
and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, and our <FONT STYLE="letter-spacing: -0.2pt">continued
ability to raise capital to fund our development, as well as those risks and uncertainties </FONT>discussed or identified in the Company&#8217;s
public filings with the AMF, including those listed in Chapter 2 &quot;Risk Factors and Internal Control&quot; of the Company's 2023
Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the <I>Autorit&eacute; des march&eacute;s financiers</I>
(&quot;AMF&quot;),</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 4.6pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 5.1pt 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 5.1pt 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1
</SUP>Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark <FONT STYLE="letter-spacing: -0.1pt">Iqirvo&reg;.</FONT></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 5.1pt 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="letter-spacing: -0.1pt"></FONT><IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 4pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/132% Lucida Sans; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="hdr.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt/132% Lucida Sans; margin: 0 5.7pt 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/132% Lucida Sans; margin: 0 5.7pt 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">which
is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those
discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission
(&quot;SEC&quot;), including the Company&#8217;s 2023 Annual Report on Form 20-F filed with the SEC on
April 5, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public,
by the Company. In addition, even if the results, performance, financial position and liquidity
of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may
not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication
of this press release. Other than as required by applicable law, the Company does not undertake any obligation
to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 7.8pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; color: #005478"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.1pt"><B>CONTACTS</B></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>GENFIT
</B>| <FONT STYLE="letter-spacing: -0.1pt">Investors</FONT></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0.05pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Lucida Sans; margin: 0.05pt 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; letter-spacing: -0.3pt">Tel:
+33 3 2016 4000 |</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">investors@genfit.com</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 3.35pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GENFIT</B> | <FONT STYLE="letter-spacing: -0.2pt">Media</FONT></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0.9pt 0 0 -20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt">Stephanie
Boyer &#8211; Press relations | Tel: +333 2016 4000 | <FONT STYLE="color: Black">stephanie.boyer@genfit.com</FONT></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt"><FONT STYLE="color: Black">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt"><FONT STYLE="color: Black">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt"><FONT STYLE="color: Black">&nbsp;</FONT></FONT></P>

<P STYLE="text-align: center; font: 10pt Lucida Sans; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt"><FONT STYLE="color: Black">&nbsp;<IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></FONT></FONT></P>

<P STYLE="text-align: right; font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt">&nbsp;3</FONT></P>

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt"><FONT STYLE="color: Black"></FONT></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Lucida Sans; margin: 0 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: -0.2pt"><FONT STYLE="color: Black">&nbsp;</FONT></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ R0,@ P$1  (1 0,1 ?_$ ,$   $% 0$!
M      ,! @0%!@ '" $  P$! 0$!              $" P0%!@<0  $# P,!
M!00$"P0&!@D% 0$" P0 $04A$@8Q05$B$P=A<3(4D=%",X&Q4F)RDM(CDU05
MH216%X*R4S06",%#8W-$->'QHK.4)54V1L)D=+0F&!$! 0 " 0,"! 0$! 0%
M!0    $1 @,A$@0Q44$3% 5A<2(R\(&14J'!0G*QT>$C8C-3@P;Q@D-C%?_:
M  P# 0 "$0,1 #\ ]1$I[KYB_P!8_7778Y<I")CNV_F*_6/UTL&:9SU]'%?K
M'ZZ+(9R);Y^VK]8U%4,A]_M6K]8_74YAX$\YT?;5^L?KIRPL.\Y?^T5^L:KH
M1Q==M<+5^L:(*C//.V^\5^L?KJXBH#RWU7'F+[OB5]=--5,P2 #^]<T_/5]=
M%)0/NR LCSW?XB_KJ%X1GER%)^_=_B+^NG!AE\P)H*BF2^/<ZOZZN1ELRLF=
MDDK(^;D:?]LY^U6F&6:8,CD;#^]R/XSG[5/!=U(<CDOYR1_&<_:HP.ZE_J&1
MM_ODC^,Y^U1@=U)_4<E_.2/XSG[5+!]U-5D,E_.2/XSG[5&#S3/ZCDOYR1_&
M<_:J<'DU61R7\Y(_C.?M48/(#F1R7\Y(_C.?M5-@R#_4LG_.R/XSG[538UE$
M1DLGVS)'\9S]JLZTB2WDLE<#YR1_&<_:IPTQG(9'^;D?QG/VJ96CB?D/YM_^
M*Y^U0BT1,_(6M\V__%<_:I)R7Y_(_P V_P#Q7/VJ!D1,[(?S;_\ %<_:H&1!
M/R _\6__ !7/KI%D1.0G_P T_P#Q7/KH*T0Y"?I_>GOXJ_KHP67&?/M_O3_\
M5?UT8$IBY^0M_O3_ /%7]="LHKF1R"?_ !;_ /%<_:HPK6F-YB>%B\M_K_M7
M/KH:-/@,U++B09+I%^UQ9_Z:K4J])QF0>4E/[Y9%NU:OKIX#10Y+Q NXH_Z1
M^NE8<JV9=<('C5])J5)*5KM?>?I-"H4O*2/B/TFE@K3?FR/M'Z31@9.^;T^(
M_2:,"4)R;V;S])I2'E#7*63HM7TFC:)R*PZZI).Y5_>:Y-F_&FPU._-,W4;%
M8OJ:F>K?:=&DN:W8$43:@!*58]:>4F^9KUI@X+OVT!VZE0[7OI'';CWU*RI)
M[Z )<]]5$$)-,G"]Z8+0#2:8-*O;0#=_MIC+@H]] .N>^D#@33!=:0=>C(=0
M':T AH!"3WT@4*-*@0*I&=>@\.O0'&@@E$]]!!F]NIIT!.%0TN:A<A6R;]33
MAV#CWTT' FF3KF@W$T@K\NK]VUJ1=1[?94VG(J5;M?$KZ33FR; '$.7T6JQ]
MIK;6HJ,L/(^VK]8U:34K>_+5^L: .E3OY:OUC0#]SGY2OI- =N<_*5])H!=R
M[?$KZ30';W/RC])^N@$NO\I7TGZZ 16^WQJ^DT!FQM!M6E1@0"XM4W8\")83
M6-Y#D2&V/HK&[M==*D(:1W&INS2<=*IL=G]M5-BO&$6]=>M7KLRNN#?$-#6T
MJ*BO%5:0K$8K&ZU5E"!--TFBB,O)!\XBLZO(?DJ-J<%4N8BK"5&U:1CLPV1;
M*'R"+7K5SU%M8T NV@$M0"$4 A%Z1F$4L&8H485 7!UJ:< (O46-(<BHK25)
M1V&B*36;VIH'!IX*P1/2EA/:>FU(8*F]Z"$OI:D#DFU!8/!N:8P?0,&.$4'A
M$D$;::M8KG%&^E2TPLL7,<:<3K;6J@>G\:R/G(0+TR;^ L%*:*(MVE@ &]9Y
M6,'NR]/)Y$*R10FT!9M3P,F;BH6HP)0UC7K2/(:;7I4LI\(#=:N7:->-9Q4?
MWEK](5$]71;T7I-;,C%&DI%?7:C)8 2[<T9&$ALW%&1@9(H+!;4&38:0/2FF
M,GTXEQ%,B@4P0B@!J% #73",I9!HR6#D.4 9*J8$2:1GT!UJ ZU(.I@AH!BC
M0"!=*@Y*ZBG! L6HRHNZC(KBJFD,F@C>M!FK3>I5"H%J(=$O5(=>@%O0"$T'
M%3GU[6F3^<?Q5GO6FL5(D IO>E$;0AD CK71HQM#<<OUUK5-,"[:VH+(B' :
M!D0$4 IM0'4&Z@$W"@&J6+4##)J>LO6KJ,CHD)2/::PVV7)E*;?&FE<NV[HU
MXQ_F#V5EWNC7C*E]9-+N7V#)=5?6KFR=M!=Z%#46-:39AMH&L!6H[*Z-*Y=H
MA/6!-=&J:@O=;]#5(0'B2JQU%%.*:7%_?7[*SIN\D)3K1!5-E=I2:TC+9ALP
MPE3I-OPULPJI4@ ^ZA)"G6@Z3;K01-NM -(H,A32,,IHJX X.M13 MI4UI#F
MQ45<2$#I1%)K0(%,AD]*"/%!'@4BIZ0:$G4@<-=* >"10"WO0#%]* AO*NFD
MN(H;W&FT2&VE @U436CX[E7HLA.OA]M/!/6<%F&WVTF^O;2L.-$F6"D6J,*R
M.RY<W)HP,I8<-,@W233!BE;0/[:81W7[&C !#YO2P$^(_P!#7-R:JUV7,*2E
M4AD=NX5SSU=$V7Y-;4@UG2D:%(-Z55 VTZTLFF-)TIQ-&2FJ(\)H(I% )>F1
M:8=3(HH!#0##0 U]*1H#JK&IR>"M+O3E%B4BJE2,FF#P: 6@$O0'4 AH!BJ
M&J@&%9'2IL.'H=)%0H\+[Z96G;KTR(:"<F@XXTE.%('7JDF[J [=01"NDJ*C
MDBOW+&O52OQ"HWC32J=#=D^^C5&XB6A6^K [RTGLK05WDBU-&'>6.Z@\')0*
M 4IL* :01K0 RLBC!F%>M .2VI1O066)*U*5<U=9BM*45B]<7)6^B>VOI7+L
M[M$A*KUFZ8DLVH Q([=*N)VAI(&H-7&&T"6\ ;7KIXZXN6(,A_6NS5C41UZ]
M4E72I.V]%.*>;F&D*L>M9TU?(S@*; TX*JI<Q;B3;6]:1ELI):0J^ZM654TA
M&U7OH9A6H#B* ;;2@&*&M!NMI2,,BBKB.Z*BG "-*FM(<@6J*N)".HHBDQKX
M13(8"PH(\4$<*1")-"3NM('$6(H!U ** $XH6H" ZH;O;W4FL.:3=0JH*GH9
M!2*J)&BLK#@M3#;\>FK: "KBBAMX>00XA(W:U.#RMXSWMHP$M+X[ZFF4O FW
M;3,I-Q3H174Z7I9"*20:8%;>4CH:FZY);8N3YDR.+Z^8G3\-8[<>%Z[-B3:H
M;!K.E2:*YJ:FKCFQK24F-=*J(HP%41P&E,D3(Y3&X]OS)TEN,@]/,4 3[AU-
M8<_D\?%,[[37\VO#X_)RW&FMV_)0/>H_%&E[?/=6#T4EI6T^XFU>;O\ ?_%U
MOK;_ "=^OV3R;\)_5*@\XXO-4$-SDMK.@0\"W_:K3^VM^#[SXO)TF^+^/1ER
M_:?(X^MUS^75>)6"D*20I)%P1J#7J2YZQY]AP501"J@&$T&$XK2IHB$Z+JJ6
MD<TG6ED5+15RLZ>":N$>%4#)P50"WH#KT EZ :30 UG2F 5 FE8"IN*G!GA5
M& 4+IX(NZC ."A2INW4E0FZD'%8IIII=%.$87 384P<.M(U-R=82U%).F]7X
MA2L/*M:7N'LJ<%E("PD5KJR(%W-6*?NTJB)N% <%=M -4^D=:""5)0#UIP K
M?0>AIDYI22K4T!/9V[=*SMZEE@D.(!LHZ5IL4&04;M*X^2-M4MH@FN6N[1-:
M M6=="0@"VAI -PJ!IRE3"LFMM:QH3ERX36VOJX>972RH+O7H:>CG0G'^VF%
M9.?%CK3H8_+E:GM#VUGL8#:%$"_=2ABJ2 G6KE9V*Z78W'95RL[%'+)W>ZJE
M18!NN:K*>TA52[AVDW49&"$BF>##8U*I"$V'?0I'<TZ_@J; "4"HL:PJ4"]1
M52)#8%_91%);=K56"R,FU $%A1:6'#4TBP(FUJ"P?84DG)%Q0#P !K0#2H &
M@(DAP;=*%Q7N.672:I495R#3U35PPV5 6JV:V@0-Q&E:1*^;BJ:2"!THL T?
M)N,N)3NJ<*RTL'-!3:03K2P,K:/D4J3UHP<2&9.XTE1+\T6O>IIF*<N*)"J$
MM:0H^RJD2&J6V+T\!.PDG?DH@2#]ZD?VU&]Z+U>AZ]M<U;FE)J:J!+3K4U4,
M2G6I6EM=*N(HZ:I+$<@]8>!XC*R\'*GO?U*.E(6W%96^HK5_U:"@*'F)[0>E
M;?2<F^N9TRYKYO'IMB]<(^/=1/0,CB^.*\>IR>>46U6[RAS<OZ*^:Y?&VTWO
M;PR[3_7R;2_\WT?%Y.O)QS/+9K?]&FMG_)!SD1G,JVR<C_4\FPA2(L/$Q[LM
MDZV6X;BU^\BO-\SAGD=-M_F<DG37CUZ3^;T?%Y+P_MT[-+ZWDVZW\HP2T+0M
M3:QM6@E*TGL(T(KY7;6RXKZ&669BZX]R[+81U(:<+T._[R(X24$?F_DGW5Z7
MV_[MR^->ESI_;_'HX/-^V\7D3K,;?W?QZO6\1FX65@MS(BKMJT4@_$A0ZI4.
M\5^A^'Y>GD<<WT]/^#XCRO&WX-[IOZ_\4W>#72YW5-H#6+U-7( INIJHY*+4
M0ZD)&E4SIUM*N)=3!2J@9=NH!;T!U (: ;8&@.VB@$*!2!-E ,*3>F'#04!V
MZIINW4E0MZ0-4:"H*R:N$>RGM-%(<)I&H^6-J4Q%MV+5^(54*J5I+@%--)YS
M@58UI$CH>TH(XOVHP'&2 *>$T(RB>E41A<4: ;M4: :&U7IE@1"5#6I/"='4
MK:*SJ:P#D9R_6M*J)<1@DB_97/O&VJP0C:;WTKFNCIUV&2\.PUCMJWUV%3(
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M?PO(U2J_=1W%A897$0\=BH#S3I7.DI*GV_LI3W4#"/#Y!)0/E3^]:4+;7/$
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MJ&0H:5R=[L[%[BX=R-*SVV:ZZ-/%A) 2+5A;AM-%BQ$3NU&E3W9.ZM+BH3(
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ME^HDQR9_QGC&<=Y9:^1\@ ;[D^9>RW.FE</-IQS'9<O4\??EN>^8>>>@8_\
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MX)F7QCZA82&1N;W?G)TI8:8B'GL1)Q@#"5"1%.J)37PK'M'93PSV5>.BO2I
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C&NB.?8?NJD$-(!.=M*KB$]451K52I,:Z5<14M'2K0?3)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B SH# 2(  A$! Q$!_\0
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MOQ%JFMP2W#7.I;/.1V4HNT8&T  C\2:G\26LU[X7U6UMHS)/-:2QQH#]YBA
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M&<Y/K1H>B6V@:>UG:O*\;323$RD$Y=BQZ <9-"VU_K7_ "!^7]:?YFE1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
